Znn3bq.jpeg
²é¿´: 1585  |  »Ø¸´: 8
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

mjjnj

ľ³æ (СÓÐÃûÆø)

[½»Á÷] Ò»¾ä»°ÇóÖú¸ßÈË£¡¼±°¡!£¨¹ØÓÚÁÙ´²·½ÃæµÄ£¬Ó¢Ò뺺£©

The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co-primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) patients¡£Sample Text

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

petrocatal

ľ³æ (ÕýʽдÊÖ)

ͨ¹ýÁÙ´²ÁÆÐ§µ÷²é,È·¶¨²¡ÈËÖеÃÒæÓÚÁÙ´²µ¼ÏòÐÔÖÎÁÆÊýÄ¿£¬¿ÉÈ·¶¨Ê×´ÎÁÆÐ§µÄ½ØÖ¹µã¡£
³ÕÃÔ¿ÆÑÐ
2Â¥2010-11-03 13:09:58
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

wust67

½ð³æ (ÖøÃûдÊÖ)

petrocatal   ÍøÓÑ·­ÒëµÃºÜºÃ£¡
3Â¥2010-11-03 13:58:57
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

wust67

½ð³æ (ÖøÃûдÊÖ)

Sample Text ¡ª¡ªÑù¶Î
4Â¥2010-11-03 13:59:43
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

mjjnj

ľ³æ (СÓÐÃûÆø)

petrocatal µÄ·­Ò뻹ÊÇûÄܰÑÒâ˼·­ÒëºÃ£¬²»¹ÜÔõÑù£¬Ö÷ÒªÁÆÐ§ÖÕµãÊÇxxxµÄÁÙ´²Ó¦´ð ÊÇÕû¸ö¾ä×ÓµÄÖ÷¸É  ÆÚ´ý¸ßÊÖ¼ÌÐø·­Ò룬лл£¡
5Â¥2010-11-03 14:05:14
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

petrocatal

ľ³æ (ÕýʽдÊÖ)

ÁÆÐ§¡°Öյ㡱ÊÇ¡°Ó¦´ð¡±»ò·´À¡µÄ¡°·­Ò롱£¬´ÓÖÐÎÄÉϽ²¾Í²»Í¬£¬¿Ï¶¨²»ÄÜÖ±Ò룡Èç´ËÈ·¶¨¾ä×ÓµÄÖ÷¸É£¬·Ç³£±ðŤ¡£¼ò¶øÑÔÖ®£¬ÖÕµãÊÇÓ¦´ð£¿£¿
½¨Ò鏸³öÉÏÏÂÎÄ£¬Õâ¶Î»°¿Ï¶¨ÓÐÏà¹ØµÄÓï¾³£¬ÐèÒª½áºÏÉÏÏÂÎÄ£¡·­Òë¸úÄã×öÔĶÁÀí½âÒ»Ñù£¡
³ÕÃÔ¿ÆÑÐ
6Â¥2010-11-03 15:17:33
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

mjjnj

ľ³æ (СÓÐÃûÆø)

TYGACIL was evaluated in adults for the treatment of complicated skin and skin structure infections (cSSSI) in two randomized, double-blind, active-controlled, multinational, multicenter studies (Studies 300 and 305). These studies compared TYGACIL (100 mg intravenous initial dose followed by 50 mg every 12 hours) with vancomycin (1 g intravenous every 12 hours)/aztreonam (2 g intravenous every 12 hours) for 5 to 14 days. Patients with complicated deep soft tissue infections including wound infections and cellulitis (¡Ý10 cm, requiring surgery/drainage or with complicated underlying disease), major abscesses, infected ulcers, and burns were enrolled in the studies. The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co-primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) patients. See Table 6. Clinical cure rates at TOC by pathogen in the microbiologically evaluable patients are presented in Table 7.
7Â¥2010-11-03 15:24:17
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

petrocatal

ľ³æ (ÕýʽдÊÖ)

ÔÚÁÙ´²ÁÆÐ§ÊµÑéµ÷²éÖУ¬Ö÷ÒªÁÆÐ§µÄÖÕµã¿É¿´×÷ÊÇÔÚÓɾ­ÁÙ´²¸Ä½øµÄµ¼ÏòÐÔÖÎÁƵIJ¡ÈËÓë¿ÉÁÙ´²ÆÀ¼Û²¡È˹¹³ÉµÄÖ÷ÒªÈËȺÖеÄÖÎÁÆÓ¦´ð¡£
population_ÈËȺ£¬ÓÃ×÷¸´Êý£¬Òâζ×Ų¡ÈË·ÖΪÁ½À࣬ÆäËûµÄ·­ÒëÓ¦¸Ã±È½Ï¼òµ¥¡£
³ÕÃÔ¿ÆÑÐ
8Â¥2010-11-03 21:22:52
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

petrocatal

ľ³æ (ÕýʽдÊÖ)

mjjnj(½ð±Ò+50, ·­ÒëEPI+1):лл£¡ 2010-11-04 09:46:01
ÔÚÁÙ´²ÁÆÐ§ÊµÑéµ÷²éÖУ¬Ö÷ÒªÁÆÐ§µÄÖÕµã¿É¿´×÷ÊÇÔÚÓɽÓÊÜÁËÁÙ´²¸Ä½øµÄµ¼ÏòÐÔÖÎÁƵIJ¡ÈËÓë¿ÉÁÙ´²ÆÀ¼ÛµÄ²¡ÈËËù¹¹³ÉµÄÖ÷ÒªÈËȺÖеÄÖÎÁÆÓ¦´ð¡£
population_ÈËȺ£¬ÓÃ×÷¸´Êý£¬Òâζ×Ų¡ÈË·ÖΪÁ½À࣬ÆäËûµÄ·­ÒëÓ¦¸Ã±È½Ï¼òµ¥¡£
³ÕÃÔ¿ÆÑÐ
9Â¥2010-11-04 08:41:58
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ mjjnj µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ²ÄÁÏ»¯¹¤×Ü·Ö334Çóµ÷¼Á +15 Riot2025 2026-04-08 15/750 2026-04-09 19:15 by Ê«Óë×ÔÓÉ
[¿¼ÑÐ] µç×ÓÐÅÏ¢270Çóµ÷¼Á +11 terminal469 2026-04-07 11/550 2026-04-09 18:28 by hy861222
[¿¼ÑÐ] 269µç×ÓÐÅÏ¢Çóµ÷¼Á£¬¿Éתרҵ +6 ¶À×Ãwl 2026-04-06 6/300 2026-04-09 17:33 by wp06
[¿¼ÑÐ] ¸´ÊÔµ÷¼Á£¬Ò»Ö¾Ô¸Ö£ÖÝ´óѧ²ÄÁÏÓ뻯¹¤289·Ö +31 ˶ÐǸ° 2026-04-08 31/1550 2026-04-09 16:54 by Delta2012
[¿¼ÑÐ] 280Çóµ÷¼Á +7 wzzzÍõ 2026-04-09 7/350 2026-04-09 15:32 by ÊÍ·ÅÌìÐÔ
[¿¼ÑÐ] һ־Ը³¶«´óѧ071000ÉúÎïѧѧ˶³õÊÔ·ÖÊý276Çóµ÷¼Á +3 Ľ¾øcc 2026-04-09 3/150 2026-04-09 09:57 by liuhuiying09
[¿¼ÑÐ] ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£©×ö¹ý·Ö×ÓʵÑé +6 ÏàÐűػá¹ââÍòÕ 2026-04-07 7/350 2026-04-08 16:49 by tjzhao
[¿¼ÑÐ] Ò»Ö¾Ô¸»ª¶«Àí¹¤085601²ÄÁϹ¤³Ì303·ÖÇóµ÷¼Á +15 a1708 2026-04-06 15/750 2026-04-08 16:23 by luoyongfeng
[¿¼ÑÐ] Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ ²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á +11 Mr. Z 2026-04-05 12/600 2026-04-08 16:15 by luoyongfeng
[¿¼ÑÐ] Çóµ÷¼Á +14 ÕÅzic 2026-04-05 15/750 2026-04-08 16:14 by Ò»Ö»ºÃ¹û×Ó?
[¿¼ÑÐ] 277Çóµ÷¼Á +4 ¿¼Ñе÷¼Álxh 2026-04-06 6/300 2026-04-08 10:40 by ÄæË®³Ë·ç
[¿¼ÑÐ] Ò»Ö¾Ô¸±±½»´ó²ÄÁϹ¤³Ì×Ü·Ö358Çóµ÷¼Á +10 cs0106 2026-04-05 12/600 2026-04-06 19:41 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] Ò»Ö¾Ô¸C9µÄ»¯Ñ§¹¤³Ì£¨085602£© 340·Ö£¬¸Ð¾õУÄÚµ÷¼ÁÎÞÍû£¬Çóµ÷¼Á +12 ÍòÊÂÒËÕé 2026-04-04 12/600 2026-04-06 07:46 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 326Çóµ÷¼Á +3 ¹ËÈô¸¡Éú 2026-04-05 3/150 2026-04-05 18:32 by À¶ÔÆË¼Óê
[¿¼ÑÐ] ¹¤¿Æ277·ÖÇóµ÷¼Á²ÄÁÏ +8 ÉÏÁËÉÏÁËÉÏŶ 2026-04-05 9/450 2026-04-05 13:05 by wwytracy
[¿¼ÑÐ] 288Çóµ÷¼Á£¬Ò»Ö¾Ô¸»ªÄÏÀí¹¤´óѧ071005 +6 ioodiiij 2026-04-04 6/300 2026-04-05 10:09 by guoweigw
[¿¼ÑÐ] 295Çóµ÷¼Á +4 AÄãºÃÑо¿Éú 2026-04-04 5/250 2026-04-04 22:46 by yu221
[¿¼ÑÐ] 085400µç×ÓÐÅÏ¢319Çóµ÷¼Á£¨½ÓÊÜ¿çרҵµ÷¼Á£© +5 ÐÇÐDz»Õ£ÑÛà¶ 2026-04-03 6/300 2026-04-04 21:50 by hemengdong
[¿¼ÑÐ] 266Çóµ÷¼Á +8 ѧԱ97LZgn 2026-04-03 8/400 2026-04-04 09:02 by 20021109
[¿¼ÑÐ] Çóµ÷¼Á»ú»á +5 ÒâȾivy 2026-04-03 5/250 2026-04-03 15:13 by qoooooo614
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û